advanced non-small cell lung cancer(NSCLC)
Conditions
Interventions
EGFR wild type group:TAXOL and DDP chemoradiotherapy
EGFR mutation group:TAXOL and DDP chemoradiotherapy
Sponsors
Guangzhou General Hospitol of Guangzhou Military Command PLA.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) pathologically confirmed patients with locally advanced (stage III) or stage VI non-squamous non-small cell lung cancer (NSCLC) who are unable or unwilling to undergo surgery. Patients with stage IV enrolled in should be resistant to targeted therapy, or are not suitable or unwilling to undergo targeted therapy. 2) Patients need and agree to receive local radiotherapy; 3) For patients with concurrent chemotherapies, the chemotherapy regimen should be PC. Those who do not want or are not suitable for concurrent chemoradiation can receive radiotherapy alone. 4) patients who voluntarily accept tissue and blood NGS test 5) age:18 to 75 years old; 6) Eastern Cooperative Oncology Group (ECOG) performance status: 0 ~ 2; 7) No serious hematopoietic function, heart, lung, liver, kidney dysfunction andimmune deficiency, the blood routine examination, liver andkidney function is normal: WBC more than 3 500/uL, haemoglobin more than 9g/dL(without blood transfusion),Platelets more than 100000/uL, total bilirubin more than 1.5*upper limit of normal, AST (SGOT)/ALT (SGPT) less than 2.5*upper limit of normal, creatinine more than 1.5*upper limit of normal; 8) contraception during and within 6 months after the treatment of subjects of childbearing age, women were given a pregnancy test within 7 days before the treatment and the results were negative. 9) understand and voluntarily participate in this study, and sign the consent. Eligible patients were over 18 years, had historical or cytological confirmation of NSCLC, need radiotherapy with or without chemotherapy. Patients were required to have NGS test before treatment.All the patient had been informed and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1) the target lesion was previously treated with radiotherapy orother local treatments within three months . 2) there are serious or not controlled diseases of lung, heart, liver and kidney. 3) accept any other antitumor treatment at the same time , while using targeted therapy for stage IV patients. 4) pregnant or lactating women. Exclusion criteria included patients received radiotherapy orother local treatments within three months ; Patients have serious or uncontrolled diseases of lung, heart, liver and kidney. ; pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactXIE BO
Guangzhou General Hospitol of Guangzhou Military Command PLA.
Outcome results
None listed